Altimmune, Inc.

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-09-13 EDT			5-day change	1st Jan Change
7.880 ^USD	+10.99%		+27.10%	-29.96%

09-10	Sector Update: Health Care Stocks Advance Late Afternoon	MT
09-10	Altimmune Shares Jump After Pemvidutide Shows Strong Lean Mass Preservation in Obesity Trial	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Altimmune, Inc.

Sector Update: Health Care Stocks Advance Late Afternoon	09-10	MT
Altimmune Shares Jump After Pemvidutide Shows Strong Lean Mass Preservation in Obesity Trial	09-10	MT
Altimmune, Inc. Announces That David J. Drutz Will Not Stand for Re-Election to the Board	08-15	CI
Transcript : Altimmune, Inc., Q2 2024 Earnings Call, Aug 08, 2024	08-08
Earnings Flash (ALT) ALTIMMUNE Reports Q2 Revenue $5,000	08-08	MT
Earnings Flash (ALT) ALTIMMUNE Reports Q2 Loss $-0.35 Per Share, vs. Street Est of Loss $-0.35 Per Share	08-08	MT
Altimmune, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-08	CI
Altimmune, Inc. Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease in Journal of Hepatology	07-25	CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell 3000 Growth Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell Microcap Growth Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell 3000E Growth Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell 2000 Growth Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell 2500 Growth Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell Small Cap Comp Growth Index	06-30	CI
Altimmune CFO Richard Eisenstadt Dies	06-26	MT
Altimmune, Inc. Appoints Andrew Shutterly as Principal Financial Officer and Principal Accounting Officer	06-26	CI
Altimmune, Inc. Appoints Andrew Shutterly as Acting Chief Financial Officer	06-26	CI
Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer	06-26	CI
Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association?s 84th Scientific Sessions	06-23	CI
Health Care Flat as Traders Wait More Obesity-Drug Updates - Health Care Roundup	06-17	DJ
Transcript : Altimmune, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 09:20 AM	06-12
Altimmune, Inc. Presents Data at EASL International Liver Congress?? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis	06-05	CI
Transcript : Altimmune, Inc. Presents at UBS Obesity Therapeutics Day, May-23-2024 10:00 AM	05-23
Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000	05-09	MT

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Employees

Sector

Biotechnology & Medical Research

Calendar

2024-09-25 - Annual General Meeting

More about the company